Lecia V Sequist

发表

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

William C Hahn, David E Root, Matthew Meyerson, 2011, Cancer discovery.

Isolation and molecular characterization of circulating melanoma cells.

Sridhar Ramaswamy, Mehmet Toner, David E Fisher, 2014, Cell reports.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Markus Riester, Cyril H Benes, S. Digumarthy, 2018, JCO precision oncology.

Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination

Sridhar Ramaswamy, Mehmet Toner, Min Yu, 2017, Nature Communications.

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Sridhar Ramaswamy, Mehmet Toner, Ben S. Wittner, 2012, Cancer discovery.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Alona Muzikansky, Thomas J Lynch, Bruce E Johnson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

Sridhar Ramaswamy, Mehmet Toner, Min Yu, 2013, Science.

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

L. Sequist, J. Engelman, Jeffrey A Engelman, 2015, The Lancet. Oncology.

Detection of mutations in EGFR in circulating lung-cancer cells.

Mehmet Toner, Alona Muzikansky, Daniel Irimia, 2008, The New England journal of medicine.

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Susan Quinn, Revathi Ananthakrishnan, Thomas J Lynch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Mari Mino-Kenudson, David C Christiani, A. Iafrate, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

Alona Muzikansky, Matthew Meyerson, Thomas J Lynch, 2007, The oncologist.

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

Gregory J Riely, Bruce E Johnson, G. Giaccone, 2009, Clinical Cancer Research.

Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study.

Naomi M Simon, Lara Traeger, N. Simon, 2017, Journal of psychosomatic research.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Mehmet Toner, Martin Peifer, Mari Mino-Kenudson, 2018, Cancer discovery.

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

David N Louis, Ultan McDermott, Jeffrey W. Clark, 2010, EMBO molecular medicine.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.

Matthew B Schabath, Pierre P Massion, Mary E Reid, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells

Mehmet Toner, Elena Brachtel, David N Louis, 2013, Science Translational Medicine.

Lung cancer screening.

Matthew B Schabath, Pierre P Massion, Mary E Reid, 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Manuel Hidalgo, Martin Schuler, Fabrice Andre, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.

Mehmet Toner, Thomas J Lynch, Sunitha Nagrath, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Marek Ancukiewicz, Thomas J Lynch, Rakesh K Jain, 2015, Proceedings of the National Academy of Sciences.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

William Pao, Yumei Pan, Lu Wang, 2012, Proceedings of the National Academy of Sciences.